DV
Dividend Vision

IMMX — Immix Biopharma Inc

Immix Biopharma Inc (IMMX)

Total return is 198.9% over the past 4.7 years, 121.4 points ahead of SPY at 77.5%. Its deepest 1-year drawdown was 39.8%.

IMMX is an equity fund focused on biopharma stocks that commenced operations in December 2021. The fund lacks readily available data on key metrics including its distribution frequency, yield profile, and expense ratio, making detailed analysis limited. The fund structure appears designed for investors interested in the biotechnology and pharmaceutical sector, though prospective investors should review the fund's prospectus for complete strategy and fee information.

IMMX key facts

Asset type
Stock
Asset class
Equity
Inception date
12/16/2021
Last close
$10.97
Market cap
$729,697,024
Average volume
1295413.0
Beta
0.089
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.92